Intrinsic value of Flexion Therapeutics, Inc. - FLXN

Previous Close

$11.93

  Intrinsic Value

$0.65

stock screener

  Rating & Target

str. sell

-95%

Previous close

$11.93

 
Intrinsic value

$0.65

 
Up/down potential

-95%

 
Rating

str. sell

We calculate the intrinsic value of FLXN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  37
  57
  85
  123
  174
  239
  321
  422
  543
  685
  851
  1,041
  1,254
  1,492
  1,755
  2,041
  2,351
  2,685
  3,041
  3,418
  3,818
  4,239
  4,680
  5,142
  5,625
  6,128
  6,653
  7,198
  7,765
  8,354
Variable operating expenses, $m
  2,695
  4,164
  6,226
  9,034
  12,745
  17,520
  23,517
  30,879
  39,734
  50,186
  62,319
  76,191
  91,836
  109,266
  128,478
  149,450
  172,154
  196,553
  222,606
  250,275
  279,524
  310,322
  342,646
  376,481
  411,822
  448,674
  487,052
  526,981
  568,499
  611,651
Fixed operating expenses, $m
  108
  111
  113
  116
  118
  121
  123
  126
  129
  132
  135
  138
  141
  144
  147
  150
  153
  157
  160
  164
  167
  171
  175
  179
  183
  187
  191
  195
  199
  204
Total operating expenses, $m
  2,803
  4,275
  6,339
  9,150
  12,863
  17,641
  23,640
  31,005
  39,863
  50,318
  62,454
  76,329
  91,977
  109,410
  128,625
  149,600
  172,307
  196,710
  222,766
  250,439
  279,691
  310,493
  342,821
  376,660
  412,005
  448,861
  487,243
  527,176
  568,698
  611,855
Operating income, $m
  -2,767
  -4,218
  -6,254
  -9,026
  -12,689
  -17,402
  -23,319
  -30,584
  -39,320
  -49,633
  -61,602
  -75,288
  -90,722
  -107,917
  -126,870
  -147,559
  -169,956
  -194,025
  -219,726
  -247,021
  -275,874
  -306,255
  -338,141
  -371,518
  -406,380
  -442,732
  -480,590
  -519,978
  -560,933
  -603,501
EBITDA, $m
  -2,763
  -4,212
  -6,247
  -9,016
  -12,675
  -17,383
  -23,294
  -30,551
  -39,278
  -49,581
  -61,539
  -75,210
  -90,629
  -107,806
  -126,739
  -147,407
  -169,781
  -193,825
  -219,500
  -246,766
  -275,590
  -305,940
  -337,793
  -371,135
  -405,962
  -442,276
  -480,095
  -519,443
  -560,356
  -602,879
Interest expense (income), $m
  1
  16
  7
  12
  19
  29
  41
  57
  77
  102
  132
  167
  208
  254
  307
  366
  430
  501
  577
  659
  747
  840
  938
  1,042
  1,150
  1,264
  1,383
  1,507
  1,636
  1,770
  1,910
Earnings before tax, $m
  -2,783
  -4,225
  -6,267
  -9,045
  -12,717
  -17,443
  -23,377
  -30,661
  -39,422
  -49,765
  -61,769
  -75,496
  -90,976
  -108,224
  -127,235
  -147,989
  -170,457
  -194,602
  -220,385
  -247,767
  -276,713
  -307,193
  -339,183
  -372,668
  -407,644
  -444,115
  -482,097
  -521,614
  -562,703
  -605,410
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -2,783
  -4,225
  -6,267
  -9,045
  -12,717
  -17,443
  -23,377
  -30,661
  -39,422
  -49,765
  -61,769
  -75,496
  -90,976
  -108,224
  -127,235
  -147,989
  -170,457
  -194,602
  -220,385
  -247,767
  -276,713
  -307,193
  -339,183
  -372,668
  -407,644
  -444,115
  -482,097
  -521,614
  -562,703
  -605,410

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  102
  157
  235
  341
  481
  661
  887
  1,165
  1,499
  1,894
  2,351
  2,875
  3,465
  4,123
  4,848
  5,639
  6,496
  7,416
  8,399
  9,443
  10,547
  11,709
  12,929
  14,205
  15,539
  16,929
  18,377
  19,884
  21,450
  23,078
Adjusted assets (=assets-cash), $m
  102
  157
  235
  341
  481
  661
  887
  1,165
  1,499
  1,894
  2,351
  2,875
  3,465
  4,123
  4,848
  5,639
  6,496
  7,416
  8,399
  9,443
  10,547
  11,709
  12,929
  14,205
  15,539
  16,929
  18,377
  19,884
  21,450
  23,078
Revenue / Adjusted assets
  0.363
  0.363
  0.362
  0.361
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
  0.362
Average production assets, $m
  18
  27
  40
  59
  83
  114
  153
  201
  258
  326
  405
  495
  597
  710
  835
  972
  1,119
  1,278
  1,447
  1,627
  1,817
  2,018
  2,228
  2,448
  2,677
  2,917
  3,167
  3,426
  3,696
  3,977
Working capital, $m
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -14
  -18
  -21
  -25
  -30
  -35
  -40
  -46
  -52
  -58
  -65
  -72
  -80
  -87
  -96
  -104
  -113
  -122
  -132
  -142
Total debt, $m
  74
  124
  194
  290
  416
  578
  781
  1,031
  1,332
  1,687
  2,099
  2,570
  3,101
  3,693
  4,346
  5,058
  5,829
  6,657
  7,542
  8,482
  9,475
  10,521
  11,618
  12,767
  13,968
  15,219
  16,522
  17,878
  19,288
  20,753
Total liabilities, $m
  91
  141
  211
  307
  433
  595
  799
  1,049
  1,349
  1,704
  2,116
  2,587
  3,119
  3,710
  4,363
  5,075
  5,846
  6,675
  7,559
  8,499
  9,492
  10,538
  11,636
  12,785
  13,985
  15,236
  16,539
  17,895
  19,305
  20,771
Total equity, $m
  10
  16
  23
  34
  48
  66
  89
  117
  150
  189
  235
  287
  347
  412
  485
  564
  650
  742
  840
  944
  1,055
  1,171
  1,293
  1,421
  1,554
  1,693
  1,838
  1,988
  2,145
  2,308
Total liabilities and equity, $m
  101
  157
  234
  341
  481
  661
  888
  1,166
  1,499
  1,893
  2,351
  2,874
  3,466
  4,122
  4,848
  5,639
  6,496
  7,417
  8,399
  9,443
  10,547
  11,709
  12,929
  14,206
  15,539
  16,929
  18,377
  19,883
  21,450
  23,079
Debt-to-equity ratio
  7.310
  7.900
  8.270
  8.490
  8.640
  8.740
  8.810
  8.850
  8.890
  8.910
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -2,783
  -4,225
  -6,267
  -9,045
  -12,717
  -17,443
  -23,377
  -30,661
  -39,422
  -49,765
  -61,769
  -75,496
  -90,976
  -108,224
  -127,235
  -147,989
  -170,457
  -194,602
  -220,385
  -247,767
  -276,713
  -307,193
  -339,183
  -372,668
  -407,644
  -444,115
  -482,097
  -521,614
  -562,703
  -605,410
Depreciation, amort., depletion, $m
  4
  5
  7
  10
  14
  19
  25
  32
  41
  52
  63
  77
  93
  111
  131
  152
  175
  200
  226
  254
  284
  315
  348
  382
  418
  456
  495
  535
  578
  621
Funds from operations, $m
  -2,779
  -4,220
  -6,259
  -9,035
  -12,703
  -17,424
  -23,352
  -30,628
  -39,380
  -49,713
  -61,706
  -75,418
  -90,883
  -108,113
  -127,105
  -147,838
  -170,282
  -194,402
  -220,159
  -247,513
  -276,429
  -306,878
  -338,835
  -372,286
  -407,226
  -443,659
  -481,602
  -521,079
  -562,126
  -604,789
Change in working capital, $m
  0
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -9
  -10
  -10
Cash from operations, $m
  -2,778
  -4,219
  -6,259
  -9,034
  -12,702
  -17,423
  -23,350
  -30,627
  -39,378
  -49,710
  -61,703
  -75,415
  -90,879
  -108,109
  -127,100
  -147,833
  -170,277
  -194,397
  -220,153
  -247,507
  -276,423
  -306,871
  -338,827
  -372,278
  -407,217
  -443,651
  -481,593
  -521,069
  -562,116
  -604,779
Maintenance CAPEX, $m
  -2
  -3
  -4
  -6
  -9
  -13
  -18
  -24
  -31
  -40
  -51
  -63
  -77
  -93
  -111
  -131
  -152
  -175
  -200
  -226
  -254
  -284
  -315
  -348
  -382
  -418
  -456
  -495
  -535
  -578
New CAPEX, $m
  -7
  -10
  -13
  -18
  -24
  -31
  -39
  -48
  -58
  -68
  -79
  -90
  -102
  -113
  -125
  -136
  -148
  -159
  -169
  -180
  -190
  -200
  -210
  -220
  -230
  -240
  -250
  -260
  -270
  -281
Cash from investing activities, $m
  -9
  -13
  -17
  -24
  -33
  -44
  -57
  -72
  -89
  -108
  -130
  -153
  -179
  -206
  -236
  -267
  -300
  -334
  -369
  -406
  -444
  -484
  -525
  -568
  -612
  -658
  -706
  -755
  -805
  -859
Free cash flow, $m
  -2,787
  -4,232
  -6,276
  -9,059
  -12,736
  -17,467
  -23,407
  -30,698
  -39,467
  -49,818
  -61,833
  -75,568
  -91,058
  -108,316
  -127,336
  -148,100
  -170,576
  -194,730
  -220,522
  -247,913
  -276,867
  -307,355
  -339,352
  -372,846
  -407,830
  -444,309
  -482,298
  -521,824
  -562,921
  -605,637
Issuance/(repayment) of debt, $m
  -84
  50
  70
  95
  126
  162
  204
  250
  301
  355
  412
  471
  531
  592
  652
  712
  771
  829
  885
  940
  993
  1,046
  1,098
  1,149
  1,200
  1,251
  1,303
  1,356
  1,410
  1,465
Issuance/(repurchase) of shares, $m
  2,905
  4,230
  6,274
  9,056
  12,731
  17,461
  23,399
  30,689
  39,455
  49,804
  61,815
  75,548
  91,035
  108,290
  127,308
  148,068
  170,543
  194,694
  220,483
  247,872
  276,824
  307,309
  339,305
  372,796
  407,777
  444,254
  482,241
  521,765
  562,860
  605,573
Cash from financing (excl. dividends), $m  
  2,821
  4,280
  6,344
  9,151
  12,857
  17,623
  23,603
  30,939
  39,756
  50,159
  62,227
  76,019
  91,566
  108,882
  127,960
  148,780
  171,314
  195,523
  221,368
  248,812
  277,817
  308,355
  340,403
  373,945
  408,977
  445,505
  483,544
  523,121
  564,270
  607,038
Total cash flow (excl. dividends), $m
  34
  49
  68
  92
  122
  156
  196
  240
  289
  341
  394
  451
  508
  566
  624
  681
  737
  792
  846
  899
  950
  1,000
  1,050
  1,099
  1,148
  1,197
  1,246
  1,297
  1,348
  1,401
Retained Cash Flow (-), $m
  -2,905
  -4,230
  -6,274
  -9,056
  -12,731
  -17,461
  -23,399
  -30,689
  -39,455
  -49,804
  -61,815
  -75,548
  -91,035
  -108,290
  -127,308
  -148,068
  -170,543
  -194,694
  -220,483
  -247,872
  -276,824
  -307,309
  -339,305
  -372,796
  -407,777
  -444,254
  -482,241
  -521,765
  -562,860
  -605,573
Prev. year cash balance distribution, $m
  222
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -2,649
  -4,182
  -6,206
  -8,963
  -12,610
  -17,305
  -23,203
  -30,448
  -39,167
  -49,464
  -61,421
  -75,097
  -90,527
  -107,724
  -126,684
  -147,387
  -169,805
  -193,902
  -219,637
  -246,973
  -275,874
  -306,309
  -338,255
  -371,697
  -406,629
  -443,057
  -480,995
  -520,468
  -561,512
  -604,171
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -2,540
  -3,828
  -5,401
  -7,380
  -9,774
  -12,559
  -15,676
  -19,031
  -22,499
  -25,932
  -29,168
  -32,047
  -34,420
  -36,165
  -37,192
  -37,454
  -36,947
  -35,709
  -33,818
  -31,383
  -28,534
  -25,416
  -22,170
  -18,931
  -15,818
  -12,926
  -10,324
  -8,052
  -6,129
  -4,549
Current shareholders' claim on cash, %
  50.0
  0.5
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

FINANCIAL RATIOS  of  Flexion Therapeutics, Inc. (FLXN)

Valuation Ratios
P/E Ratio -5.2
Price to Sales 0
Price to Book 2
Price to Tangible Book
Price to Cash Flow -6.1
Price to Free Cash Flow -5.4
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 60%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 23
Current Ratio 0.1
LT Debt to Equity 11.8%
Total Debt to Equity 16.6%
Interest Coverage -71
Management Effectiveness
Return On Assets -40.2%
Ret/ On Assets - 3 Yr. Avg. -34.6%
Return On Total Capital -42.7%
Ret/ On T. Cap. - 3 Yr. Avg. -36.7%
Return On Equity -49.5%
Return On Equity - 3 Yr. Avg. -40.4%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

FLXN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the FLXN stock intrinsic value calculation we used $23 million for the last fiscal year's total revenue generated by Flexion Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Flexion Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our FLXN stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for FLXN is calculated based on our internal credit rating of Flexion Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Flexion Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of FLXN stock the variable cost ratio is equal to 7326.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $106 million in the base year in the intrinsic value calculation for FLXN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for Flexion Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Flexion Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the FLXN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for FLXN are equal to 47.6%.

Life of production assets of 6.4 years is the average useful life of capital assets used in Flexion Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for FLXN is equal to -1.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $110.079 million for Flexion Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 37.993 million for Flexion Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Flexion Therapeutics, Inc. at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
RDUS Radius Health, 18.80 0.29  str.sell
HZNP Horizon Pharma 27.66 3.58  str.sell
ABBV AbbVie Inc. 80.65 31.53  str.sell

CONTACT US       ASSET ALLOCATION

About X-FIN       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2019. All rigths reserved.